{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:11:38Z","timestamp":1782951098814,"version":"3.54.5"},"reference-count":105,"publisher":"Georg Thieme Verlag KG","issue":"03","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Catastrophic thrombosis is a severe condition characterized by a hypercoagulable tendency, leading to multiple thromboembolic events in different blood vessels, usually within a short timeframe. Several conditions have been associated with the development of catastrophic thrombosis, including the catastrophic antiphospholipid syndrome, thrombotic anti-platelet factor 4 immune disorders, thrombotic microangiopathies, cancers, the hyper-eosinophilic syndrome, pregnancy, infections, trauma, and drugs. Thrombotic storm represents a medical emergency whose management represents a serious challenge for physicians. Besides the prompt start of anticoagulation, a patient's prognosis depends on early recognition and possible treatment of the underlying condition. In this narrative review, we summarize the main characteristics of catastrophic thrombosis, analyzing the various conditions triggering such life-threatening complication. Finally, an algorithm with the diagnostic workup and the initial management of patients with catastrophic thrombosis is presented.<\/jats:p>","DOI":"10.1055\/s-0044-1788790","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T23:30:11Z","timestamp":1723851011000},"page":"312-321","source":"Crossref","is-referenced-by-count":4,"title":["Catastrophic Thrombosis: A Narrative Review"],"prefix":"10.1055","volume":"51","author":[{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Focosi","sequence":"additional","affiliation":[{"name":"North-Western Tuscany Blood Bank, Pisa University Hospital, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Piergiulio","family":"Pezzo","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine and Hematology, Carlo Poma Hospital, Mantova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Mannuccio","family":"Mannucci","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"issue":"06","key":"ref1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1586\/ehm.12.56","article-title":"Clinical causes and treatment of the thrombotic storm","volume":"5","author":"T L Ortel","year":"2012","journal-title":"Expert Rev Hematol"},{"issue":"04","key":"ref2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.amjmed.2010.10.018","article-title":"Thrombotic storm revisited: preliminary diagnostic criteria suggested by the thrombotic storm study group","volume":"124","author":"C S Kitchens","year":"2011","journal-title":"Am J Med"},{"issue":"04","key":"ref3","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0002-9343(98)00061-8","article-title":"Thrombotic storm: when thrombosis begets thrombosis","volume":"104","author":"C S Kitchens","year":"1998","journal-title":"Am J Med"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2014-09-551978","article-title":"How I treat catastrophic thrombotic syndromes","volume":"126","author":"T L Ortel","year":"2015","journal-title":"Blood"},{"issue":"07","key":"ref5","first-page":"768","article-title":"Thrombotic microangiopathy: an under-recognized cause of catastrophic thrombosis","volume":"46","author":"V Vassiliou","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"ref6","first-page":"792748","article-title":"Catastrophic antiphospholipid syndrome: a review of the recent literature","volume":"12","author":"A Georgakopoulos","year":"2021","journal-title":"Front Immunol"},{"issue":"04","key":"ref7","first-page":"822","article-title":"Thrombotic microangiopathy in critically ill patients: a review on pathophysiology, diagnosis, and therapy","volume":"10","author":"F Boissier","year":"2021","journal-title":"J Clin Med"},{"issue":"11","key":"ref8","first-page":"1844","article-title":"Thrombotic microangiopathy and associated renal disorders","volume":"35","author":"S Chaturvedi","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"100743","DOI":"10.1016\/j.blre.2020.100743","article-title":"The looming storm: blood and cytokines in COVID-19","volume":"46","author":"S Kaur","year":"2021","journal-title":"Blood Rev"},{"issue":"17","key":"ref10","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.2174\/1389450124666221025102929","article-title":"COVID-19 induces cytokine storm and dysfunctional hemostasis","volume":"23","author":"J Charles","year":"2022","journal-title":"Curr Drug Targets"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12185-020-03029-y","article-title":"COVID-19-associated coagulopathy and disseminated intravascular coagulation","volume":"113","author":"H Asakura","year":"2021","journal-title":"Int J Hematol"},{"issue":"07","key":"ref12","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1055\/s-0040-1712156","article-title":"Coronavirus disease 2019 coagulopathy: disseminated intravascular coagulation and thrombotic microangiopathy-either, neither, or both","volume":"46","author":"M Levi","year":"2020","journal-title":"Semin Thromb Hemost"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.thromres.2021.04.012","article-title":"COVID-19 and thrombotic microangiopathies","volume":"202","author":"N R Tiwari","year":"2021","journal-title":"Thromb Res"},{"issue":"04","key":"ref14","first-page":"508","article-title":"The catastrophic antiphospholipid syndrome","volume":"19","author":"R A Asherson","year":"1992","journal-title":"J Rheumatol"},{"issue":"02","key":"ref15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.autrev.2010.08.005","article-title":"Catastrophic antiphospholipid syndrome: updated diagnostic algorithms","volume":"10","author":"D Erkan","year":"2010","journal-title":"Autoimmun Rev"},{"issue":"07","key":"ref16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1191\/0961203303lu394oa","article-title":"Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines","volume":"12","author":"R A Asherson","year":"2003","journal-title":"Lupus"},{"issue":"03","key":"ref17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/BOR.0000000000000932","article-title":"Antiphospholipid syndrome management: a 2023 update and practical algorithm-based approach","volume":"35","author":"A Ambati","year":"2023","journal-title":"Curr Opin Rheumatol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e069717","DOI":"10.1136\/bmj-2021-069717","article-title":"Antiphospholipid syndrome: advances in diagnosis, pathogenesis, and management","volume":"380","author":"J S Knight","year":"2023","journal-title":"BMJ"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1055\/s-0043-1776318","article-title":"Classification criteria for the antiphospholipid syndrome: not the same as diagnostic criteria for antiphospholipid syndrome","volume":"50","author":"E J Favaloro","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1055\/s-0043-1764472","article-title":"Pediatric presentation of antiphospholipid syndrome: a review of recent literature with estimation of local prevalence","volume":"50","author":"M Radin","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1055\/s-0043-1776910","article-title":"Risk factors for antiphospholipid antibodies and antiphospholipid syndrome","volume":"50","author":"R Aguirre Del-Pino","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"08","key":"ref22","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1055\/s-0042-1749590","article-title":"Antiphospholipid syndrome in patients with venous thromboembolism","volume":"49","author":"V Pengo","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref23","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1055\/s-0042-1760333","article-title":"Evolution of antiphospholipid syndrome","volume":"49","author":"D RJ Arachchillage","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"02","key":"ref24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0043-1771268","article-title":"Are antiphospholipid antibodies a surrogate risk factor for thrombosis in sepsis?","volume":"50","author":"J Thachil","year":"2024","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref25","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1055\/s-0041-1725057","article-title":"Arterial thrombosis in patients with antiphospholipid syndrome: a review and meta-analysis","volume":"47","author":"J Aibar","year":"2021","journal-title":"Semin Thromb Hemost"},{"issue":"07","key":"ref26","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1055\/s-0043-1767728","article-title":"Thrombotic antiphospholipid syndrome and direct oral anticoagulants: unmet needs and review of the literature","volume":"49","author":"A Marco-Rico","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1055\/s-0041-1728832","article-title":"COVID-19 and antiphospholipid antibodies: time for a reality check?","volume":"48","author":"E J Favaloro","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"01","key":"ref28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1055\/s-0042-1758118","article-title":"\u201cTrue\u201d antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid autoantibodies","volume":"49","author":"R Arcani","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"04","key":"ref29","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1055\/s-0042-1756193","article-title":"Antiphospholipid antibodies in pregnancy: maternal and neonatal implications","volume":"49","author":"J C Gris","year":"2023","journal-title":"Semin Thromb Hemost"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/immuno4010001","article-title":"Catastrophic antiphospholipid syndrome: a review","volume":"4","author":"C Siniscalchi","year":"2024","journal-title":"Immuno"},{"issue":"01","key":"ref31","doi-asserted-by":"crossref","first-page":"668","DOI":"10.3390\/ijms25010668","article-title":"Catastrophic antiphospholipid syndrome","volume":"25","author":"V Bitsadze","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"03","key":"ref32","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/jth.15082","article-title":"Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications","volume":"19","author":"S Chaturvedi","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"01","key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2008.10.003","article-title":"The physiopathology of the catastrophic antiphospholipid (Asherson's) syndrome: compelling evidence","volume":"32","author":"O D Ortega-Hernandez","year":"2009","journal-title":"J Autoimmun"},{"issue":"04","key":"ref34","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1080\/17474086.2017.1300522","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome","volume":"10","author":"O Carmi","year":"2017","journal-title":"Expert Rev Hematol"},{"issue":"12","key":"ref35","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.autrev.2016.09.010","article-title":"Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry","volume":"15","author":"I Rodr\u00edguez-Pint\u00f3","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"12","key":"ref36","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/0961203320951260","article-title":"16th International Congress on Antiphospholipid Antibodies Task Force report on catastrophic antiphospholipid syndrome","volume":"29","author":"R Cervera","year":"2020","journal-title":"Lupus"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1111\/jth.14192","article-title":"McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome","volume":"16","author":"K Legault","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/rheumatology\/key082","article-title":"The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients","volume":"57","author":"I Rodr\u00edguez-Pint\u00f3","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"01","key":"ref39","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3390\/antib13010021","article-title":"Diagnosis and management of catastrophic antiphospholipid syndrome and the potential impact of the 2023 ACR\/EULAR antiphospholipid syndrome classification criteria","volume":"13","author":"L Jacobs","year":"2024","journal-title":"Antibodies (Basel)"},{"issue":"03","key":"ref40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/00005792-199805000-00005","article-title":"Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients","volume":"77","author":"R A Asherson","year":"1998","journal-title":"Medicine (Baltimore)"},{"issue":"08","key":"ref41","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/art.22018","article-title":"Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients","volume":"54","author":"S Bucciarelli","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"06","key":"ref42","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/ard.62.6.530","article-title":"Long term outcome of catastrophic antiphospholipid syndrome survivors","volume":"62","author":"D Erkan","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"01","key":"ref43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2023000503","article-title":"Thrombotic anti-PF4 immune disorders: HIT, VITT, and beyond","volume":"2023","author":"A Greinacher","year":"2023","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"02","key":"ref44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.seminhematol.2022.02.005","article-title":"Platelet-activating anti-PF4 disorders: an overview","volume":"59","author":"T E Warkentin","year":"2022","journal-title":"Semin Hematol"},{"issue":"04","key":"ref45","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.htct.2023.11.012","article-title":"Anti-PF4 antibodies and their relationship with COVID infection","volume":"46","author":"C Yang","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"issue":"06","key":"ref46","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1055\/s-0042-1758818","article-title":"Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review","volume":"49","author":"T E Warkentin","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"06","key":"ref47","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/MCC.0000000000000259","article-title":"Heparin-induced thrombocytopenia","volume":"21","author":"T E Warkentin","year":"2015","journal-title":"Curr Opin Crit Care"},{"issue":"08","key":"ref48","doi-asserted-by":"crossref","first-page":"102245","DOI":"10.1016\/j.rpth.2023.102245","article-title":"Heparin-induced thrombocytopenia (and autoimmune heparin-induced thrombocytopenia): an illustrious review","volume":"7","author":"T E Warkentin","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"101155","DOI":"10.1016\/j.blre.2023.101155","article-title":"Platelet factor 4(PF4) and its multiple roles in diseases","volume":"64","author":"Z Liu","year":"2024","journal-title":"Blood Rev"},{"issue":"15","key":"ref50","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1182\/blood.2018881607","article-title":"Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation","volume":"135","author":"I Johnston","year":"2020","journal-title":"Blood"},{"issue":"S 01","key":"ref51","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/ijlh.13564","article-title":"Diagnosing heparin-induced thrombocytopenia: the need for accuracy and speed","volume":"43","author":"A M Pishko","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"21","key":"ref52","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.3390\/jcm12216921","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"12","author":"T E Warkentin","year":"2023","journal-title":"J Clin Med"},{"issue":"11","key":"ref53","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/jth.13813","article-title":"Autoimmune heparin-induced thrombocytopenia","volume":"15","author":"A Greinacher","year":"2017","journal-title":"J Thromb Haemost"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.thromres.2021.05.018","article-title":"Spontaneous HIT syndrome: knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia","volume":"204","author":"T E Warkentin","year":"2021","journal-title":"Thromb Res"},{"issue":"22","key":"ref55","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/bloodadvances.2018024489","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia","volume":"2","author":"A Cuker","year":"2018","journal-title":"Blood Adv"},{"issue":"03","key":"ref56","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/blood-2016-01-635003","article-title":"How I treat patients with a history of heparin-induced thrombocytopenia","volume":"128","author":"T E Warkentin","year":"2016","journal-title":"Blood"},{"issue":"02","key":"ref57","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/ejh.13665","article-title":"COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome","volume":"107","author":"M Franchini","year":"2021","journal-title":"Eur J Haematol"},{"issue":"03","key":"ref58","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/jth.15604","article-title":"Thrombosis and thrombocytopenia after HPV vaccination","volume":"20","author":"S Johansen","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"19","key":"ref59","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.3390\/jcm12196126","article-title":"Vaccine-induced immune thrombocytopenia and thrombosis (VITT)-insights from clinical cases, in vitro studies and murine models","volume":"12","author":"V AS Dabbiru","year":"2023","journal-title":"J Clin Med"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"oeac036","DOI":"10.1093\/ehjopen\/oeac036","article-title":"Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway","volume":"2","author":"F Salih","year":"2022","journal-title":"Eur Heart J Open"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1155727","DOI":"10.3389\/fmed.2023.1155727","article-title":"Vaccine-induced immune thrombotic thrombocytopenia: what do we know hitherto?","volume":"10","author":"R Roytenberg","year":"2023","journal-title":"Front Med (Lausanne)"},{"issue":"14","key":"ref62","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1182\/blood.2022017696","article-title":"Vaccine-induced immune thrombotic thrombocytopenia","volume":"141","author":"D B Cines","year":"2023","journal-title":"Blood"},{"issue":"22","key":"ref63","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","article-title":"Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination","volume":"384","author":"A Greinacher","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"ref64","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1111\/jth.15881","article-title":"Assessment of immunological anti-platelet factor 4 antibodies for vaccine-induced thrombotic thrombocytopenia (VITT) in a large Australian cohort: a multicenter study comprising 1284 patients","volume":"20","author":"E J Favaloro","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"06","key":"ref65","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.jtha.2024.02.011","article-title":"2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19","volume":"22","author":"S Schulman","year":"2024","journal-title":"J Thromb Haemost"},{"issue":"2195","key":"ref66","doi-asserted-by":"crossref","first-page":"n2195","DOI":"10.1136\/bmj.n2195","article-title":"Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance","volume":"375","author":"S Pavord","year":"2021","journal-title":"BMJ"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/j.seminhematol.2022.03.002","article-title":"Treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT)","volume":"59","author":"N Gabarin","year":"2022","journal-title":"Semin Hematol"},{"issue":"04","key":"ref68","first-page":"281","article-title":"Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET)","volume":"19","author":"P Gresele","year":"2021","journal-title":"Blood Transfus"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.semarthrit.2013.11.004","article-title":"Thrombotic microangiopathies","volume":"43","author":"M H Rosove","year":"2014","journal-title":"Semin Arthritis Rheum"},{"issue":"07","key":"ref70","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"J N George","year":"2014","journal-title":"N Engl J Med"},{"issue":"03","key":"ref71","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.emc.2014.04.008","article-title":"Thrombotic microangiopathies (TTP, HUS, HELLP)","volume":"32","author":"S Kappler","year":"2014","journal-title":"Emerg Med Clin North Am"},{"issue":"08","key":"ref72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1056\/NEJMra020528","article-title":"Thrombotic microangiopathies","volume":"347","author":"J L Moake","year":"2002","journal-title":"N Engl J Med"},{"issue":"21","key":"ref73","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"B S Joly","year":"2017","journal-title":"Blood"},{"issue":"08","key":"ref74","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1055\/s-0042-1749589","article-title":"Thrombotic thrombocytopenic purpura: from 1972 to 2022 and beyond","volume":"48","author":"J N George","year":"2022","journal-title":"Semin Thromb Hemost"},{"issue":"03","key":"ref75","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1055\/s-0042-1758059","article-title":"From the discovery of ADAMTS13 to current understanding of its role in health and disease","volume":"49","author":"A I Woods","year":"2023","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"ref76","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1182\/blood.V87.10.4235.bloodjournal87104235","article-title":"Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion","volume":"87","author":"H M Tsai","year":"1996","journal-title":"Blood"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.mcna.2016.09.010","article-title":"Syndromes of thrombotic microangiopathy","volume":"101","author":"J J Shatzel","year":"2017","journal-title":"Med Clin North Am"},{"issue":"06","key":"ref78","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura","volume":"325","author":"G A Rock","year":"1991","journal-title":"N Engl J Med"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"17020","DOI":"10.1038\/nrdp.2017.20","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"J A Kremer Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"01","key":"ref80","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1055\/a-2223-9484","article-title":"100 years of thrombotic thrombocytopenic purpura: a story of death and life","volume":"44","author":"B L\u00e4mmle","year":"2024","journal-title":"Hamostaseologie"},{"issue":"06","key":"ref81","first-page":"2019","article-title":"Treatment of immune-mediated thrombotic thrombocytopenic purpura without plasma exchange","volume":"109","author":"M Capecchi","year":"2024","journal-title":"Haematologica"},{"issue":"18","key":"ref82","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1056\/NEJMoa2402567","article-title":"Recombinant ADAMTS13 for immune thrombotic thrombocytopenic purpura","volume":"390","author":"P K Bendapudi","year":"2024","journal-title":"N Engl J Med"},{"issue":"15","key":"ref83","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMra2108739","article-title":"Shiga toxin-producing Escherichia coli and the hemolytic-uremic syndrome","volume":"389","author":"S B Freedman","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"ref84","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1515\/cclm-2015-0024","article-title":"Atypical hemolytic uremic syndrome: from diagnosis to treatment","volume":"53","author":"M Franchini","year":"2015","journal-title":"Clin Chem Lab Med"},{"issue":"01","key":"ref85","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/1744-9987.12763","article-title":"Atypical hemolytic-uremic syndrome: an update on pathophysiology, diagnosis, and treatment","volume":"23","author":"R Raina","year":"2019","journal-title":"Ther Apher Dial"},{"issue":"23","key":"ref86","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","article-title":"Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome","volume":"368","author":"C M Legendre","year":"2013","journal-title":"N Engl J Med"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.2147\/JMDH.S245620","article-title":"Atypical hemolytic-uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management","volume":"16","author":"K Yerigeri","year":"2023","journal-title":"J Multidiscip Healthc"},{"issue":"08","key":"ref88","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1038\/s41409-021-01283-0","article-title":"Transplant-associated thrombotic microangiopathy: theoretical considerations and a practical approach to an unrefined diagnosis","volume":"56","author":"J A Young","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/hematology.2022000367","article-title":"Approach to the patient with suspected hypereosinophilic syndrome","volume":"2022","author":"A D Klion","year":"2022","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"issue":"05","key":"ref90","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/ajh.27287","article-title":"World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management","volume":"99","author":"W Shomali","year":"2024","journal-title":"Am J Hematol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"1424749","DOI":"10.1155\/2022\/1424749","article-title":"Rare case of a young male presented with abdominal pain, solid colon tumors, and eosinophilia, followed by tremendous thromboembolic complications and eventually diagnosed with idiopathic hypereosinophilic syndrome","volume":"2022","author":"T Zemleduch","year":"2022","journal-title":"Case Rep Med"},{"key":"ref92","first-page":"213","article-title":"Acute pulmonary embolism and deep vein thrombosis secondary to idiopathic hypereosinophilic syndrome","volume":"25","author":"D Li","year":"2018","journal-title":"Respir Med Case Rep"},{"issue":"06","key":"ref93","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.12998\/wjcc.v10.i6.1952","article-title":"Eosinophilia complicated with venous thromboembolism: a case report","volume":"10","author":"W Q Su","year":"2022","journal-title":"World J Clin Cases"},{"issue":"03","key":"ref94","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2169\/internalmedicine.51.6156","article-title":"Hypereosinophilic syndrome associated with simultaneous intracardiac thrombi, cerebral thromboembolism and pulmonary embolism","volume":"51","author":"D Buyuktas","year":"2012","journal-title":"Intern Med"},{"issue":"01","key":"ref95","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13223-022-00666-2","article-title":"Hypereosinophilic syndrome presenting as coagulopathy","volume":"18","author":"K Aukstuolis","year":"2022","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"04","key":"ref96","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/bjh.12729","article-title":"Catastrophic thrombosis in idiopathic hypereosinophilic syndrome","volume":"165","author":"S Todd","year":"2014","journal-title":"Br J Haematol"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jaci.2012.12.1105","article-title":"Hypereosinophilic syndrome and thrombosis: a retrospective review","volume":"131","author":"K L Wallace","year":"2013","journal-title":"J Allergy Clin Immunol"},{"issue":"08","key":"ref98","doi-asserted-by":"crossref","first-page":"e2119812","DOI":"10.1001\/jamanetworkopen.2021.19812","article-title":"Association of thrombosis with hypereosinophilic syndrome in patients with genetic alterations","volume":"4","author":"O Leiva","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"ref99","doi-asserted-by":"crossref","first-page":"e111862","DOI":"10.1371\/journal.pone.0111862","article-title":"Enhanced tissue factor expression by blood eosinophils from patients with hypereosinophilia: a possible link with thrombosis","volume":"9","author":"M Cugno","year":"2014","journal-title":"PLoS One"},{"issue":"02","key":"ref100","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2005-05-2152","article-title":"The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states","volume":"107","author":"J G Wang","year":"2006","journal-title":"Blood"},{"issue":"21","key":"ref101","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019000518","article-title":"Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps","volume":"134","author":"C Marx","year":"2019","journal-title":"Blood"},{"issue":"07","key":"ref102","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/cancers16071383","article-title":"Clinical and therapeutic intervention of hypereosinophilia in the era of molecular diagnosis","volume":"16","author":"L Nguyen","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"04","key":"ref103","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.thromres.2012.11.024","article-title":"Thrombosis in acute promyelocytic leukemia","volume":"131","author":"A Rashidi","year":"2013","journal-title":"Thromb Res"},{"issue":"02","key":"ref104","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/1076029616683802","article-title":"Oral contraceptives and HRT risk of thrombosis","volume":"24","author":"A Gialeraki","year":"2018","journal-title":"Clin Appl Thromb Hemost"},{"issue":"25","key":"ref105","doi-asserted-by":"crossref","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","article-title":"Thrombosis in paroxysmal nocturnal hemoglobinuria","volume":"121","author":"A Hill","year":"2013","journal-title":"Blood"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0044-1788790.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:35:55Z","timestamp":1741908955000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0044-1788790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":105,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,3,13]]},"published-print":{"date-parts":[[2025,4]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0044-1788790","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}